ST Pharm Co.,Ltd.

KOSDAQ:A237690 Stock Report

Market Cap: ₩1.9t

ST PharmLtd Future Growth

Future criteria checks 4/6

ST PharmLtd is forecast to grow earnings and revenue by 31.6% and 19.8% per annum respectively. EPS is expected to grow by 30.5% per annum. Return on equity is forecast to be 13.3% in 3 years.

Key information

31.6%

Earnings growth rate

30.5%

EPS growth rate

Pharmaceuticals earnings growth31.3%
Revenue growth rate19.8%
Future return on equity13.3%
Analyst coverage

Good

Last updated23 Dec 2024

Recent future growth updates

Recent updates

Should You Be Adding ST PharmLtd (KOSDAQ:237690) To Your Watchlist Today?

Nov 22
Should You Be Adding ST PharmLtd (KOSDAQ:237690) To Your Watchlist Today?

ST Pharm Co.,Ltd.'s (KOSDAQ:237690) Shares Climb 29% But Its Business Is Yet to Catch Up

Aug 30
ST Pharm Co.,Ltd.'s (KOSDAQ:237690) Shares Climb 29% But Its Business Is Yet to Catch Up

Is Now The Time To Put ST PharmLtd (KOSDAQ:237690) On Your Watchlist?

Aug 17
Is Now The Time To Put ST PharmLtd (KOSDAQ:237690) On Your Watchlist?

Is ST Pharm Co.,Ltd. (KOSDAQ:237690) Trading At A 41% Discount?

May 09
Is ST Pharm Co.,Ltd. (KOSDAQ:237690) Trading At A 41% Discount?

Why ST PharmLtd's (KOSDAQ:237690) Earnings Are Better Than They Seem

Mar 22
Why ST PharmLtd's (KOSDAQ:237690) Earnings Are Better Than They Seem

ST Pharm Co.,Ltd. (KOSDAQ:237690) Stock Rockets 54% As Investors Are Less Pessimistic Than Expected

Mar 18
ST Pharm Co.,Ltd. (KOSDAQ:237690) Stock Rockets 54% As Investors Are Less Pessimistic Than Expected

Investors Who Bought ST PharmLtd (KOSDAQ:237690) Shares A Year Ago Are Now Up 221%

Mar 16
Investors Who Bought ST PharmLtd (KOSDAQ:237690) Shares A Year Ago Are Now Up 221%

Calculating The Fair Value Of ST Pharm Co.,Ltd. (KOSDAQ:237690)

Jan 22
Calculating The Fair Value Of ST Pharm Co.,Ltd. (KOSDAQ:237690)

What Type Of Shareholders Own The Most Number of ST Pharm Co.,Ltd. (KOSDAQ:237690) Shares?

Dec 23
What Type Of Shareholders Own The Most Number of ST Pharm Co.,Ltd. (KOSDAQ:237690) Shares?

Health Check: How Prudently Does ST PharmLtd (KOSDAQ:237690) Use Debt?

Nov 26
Health Check: How Prudently Does ST PharmLtd (KOSDAQ:237690) Use Debt?

Earnings and Revenue Growth Forecasts

KOSDAQ:A237690 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027578,150N/A28,000N/A4
12/31/2026451,79870,42953,33365,63310
12/31/2025366,38853,20018,00046,97810
12/31/2024292,84743,16015,66755,2758
9/30/2024278,64332,389-3,66453,124N/A
6/30/2024272,88721,706-23,24322,468N/A
3/31/2024286,06922,027-31,8258,854N/A
12/31/2023284,99219,581-42,1451,298N/A
9/30/2023264,76011,544-46,3087,917N/A
6/30/2023269,63817,810-37,32124,400N/A
3/31/2023262,98719,882-36,39431,641N/A
12/31/2022249,32218,000-53,3397,031N/A
9/30/2022200,65910,981-57,5751,971N/A
6/30/2022186,1308,285-50,0226,557N/A
3/31/2022175,36310,241-37,81214,203N/A
12/31/2021165,6423,312-44,6487,270N/A
9/30/2021161,6893,841-43,776489N/A
6/30/2021137,778-10,640-35,930-4N/A
3/31/2021131,198-13,064-46,419-23,126N/A
12/31/2020124,109-12,147-38,379-20,935N/A
9/30/2020115,724-17,794-35,929-28,123N/A
6/30/2020113,385-11,788-39,485-31,636N/A
3/31/202097,736-17,366-27,574-20,374N/A
12/31/201993,257-18,529-36,608-30,517N/A
9/30/201974,084-17,228-32,516-25,384N/A
6/30/201967,420-22,920-37,753-22,816N/A
3/31/201985,107-15,330-34,743-17,456N/A
12/31/201897,738-9,268-16,54510,767N/A
9/30/2018132,3996,823-13,73221,795N/A
6/30/2018162,38021,376N/A37,041N/A
3/31/2018183,30032,346N/A44,234N/A
12/31/2017202,80044,997N/A54,437N/A
9/30/2017193,63948,990N/A55,544N/A
6/30/2017204,25357,391N/A63,059N/A
3/31/2017217,29165,196N/A78,773N/A
12/31/2016200,36261,426N/A50,778N/A
9/30/2016198,74058,742N/A75,467N/A
6/30/2016190,49554,579N/A65,683N/A
12/31/2015138,05225,189N/A35,822N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A237690's forecast earnings growth (31.6% per year) is above the savings rate (2.7%).

Earnings vs Market: A237690's earnings (31.6% per year) are forecast to grow faster than the KR market (29.1% per year).

High Growth Earnings: A237690's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: A237690's revenue (19.8% per year) is forecast to grow faster than the KR market (9.2% per year).

High Growth Revenue: A237690's revenue (19.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: A237690's Return on Equity is forecast to be low in 3 years time (13.3%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 16:57
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ST Pharm Co.,Ltd. is covered by 20 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Heeyoung LeeDaishin Securities Co. Ltd.
Yoonjin LimDaishin Securities Co. Ltd.
Jisoo LeeDAOL Investment & Securities Co., Ltd.